Theralase Technologies Inc. V.TLT

33.3% CR rate, with 50.0% data pending

[floatinketucky]

In total 6 patients were treated using the Study II treatment optimizations. A preliminary analysis of the primary objective at 90 days for patients receiving the optimized primary Study Treatment demonstrates a 33.3% CR rate, with 50.0% data pending and only 16.7% with no response.

[floatinketucky]

In support of the tertiary objective, all patients have experienced some transient grade 1 or grade 2 AEs (e.g.: bladder spasms, constipation, urge incontinence, fatigue, urinary frequency, hematuria, penile discomfort, urinary urgency, pain, urinary tract infections and other) where > 80% have completely resolved with 180 days. Very good!!!!!

[Oilminerdeluxe]

We are most definitely back in the game, imho. Next quarterly will be damn exctining.

[CancerSlayer]

  Good point floatinketucky!  We can't forget about SAFETY.  Safety plays a major role in an FDA approval, & TLT can boast one of the safest so far...& leading the pack in fewest treatments.  Our high efficacy so far in optimized patients (80% CR in evaluable patients, including the two from Ph 1) certainly adds significant promise to our chances for approval

[floatinketucky]

Yeah, I set some powder to the side for this. I expected the data to be early to show the real effect of the treatment. I did expect the market to have a purge of day and swing traders exiting positions.